Upconversion nanoparticle-based optical biosensor for early diagnosis of stroke.

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Clinical Diagnostics

Background:

• Stroke affects over 17 million annually, necessitating rapid diagnosis to differentiate ischemic from hemorrhagic types.
• Current diagnostic methods can be time-consuming, and stroke mimics (e.g., migraine, seizures) complicate early intervention.
• A simple, rapid blood biomarker test is crucial for efficient prehospital and emergency stroke management.

Purpose of the Study:

• To develop and validate a proof-of-concept optical biosensor for detecting glial fibrillary acidic protein (GFAP) as a stroke biomarker.
• To assess the feasibility of using lanthanide-doped upconversion nanoparticles (UCNPs) for GFAP detection in human blood serum.
• To provide a complementary diagnostic tool for rapid stroke identification in emergency settings.

Main Methods:

• Development of a lanthanide-doped upconversion nanoparticle (UCNP)-based optical biosensor platform.
• Conjugation of UCNPs with antibodies specific to glial fibrillary acidic protein (GFAP).
• Measurement of photoluminescence quenching response to varying GFAP concentrations in human blood serum.

Main Results:

• Demonstrated a linear correlation between GFAP concentration and the photoluminescence quenching of UCNP-conjugated antibodies.
• Successfully detected the potential stroke biomarker GFAP in human blood serum samples.
• Established a proof-of-concept for a UCNP-based optical biosensor platform for biomarker detection.

Conclusions:

• The UCNP-based optical biosensor shows promise for rapid GFAP detection, aiding in differentiating stroke from stroke mimics.
• This technology can be implemented in ambulances and emergency departments for faster stroke diagnosis and treatment.
• Future integration into self-assessment kits could enable remote monitoring for at-risk patients.